Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited has announced that its Benidipine Hydrochloride, used for treating primary hypertension and angina pectoris, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step for the company in enhancing its product offerings and could potentially strengthen its position in the pharmaceutical market, benefiting both shareholders and potential investors.
More about SSY Group
SSY Group Limited is a company involved in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. Its primary products include medications for treating hypertension and angina pectoris, with a specific market focus on the Chinese healthcare sector.
YTD Price Performance: 1.86%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.3B
For an in-depth examination of 2005 stock, go to TipRanks’ Stock Analysis page.